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Lactate dehydrogenase A (LDH-A) is a key enzyme in
anaerobic respiration that is predominantly found in skeletal
muscle and catalyses the reversible conversion of pyruvate to
lactate in the presence of NADH. LDH-A is overexpressed
in many tumours and has therefore emerged as an attractive
target for anticancer drug discovery. Crystal structures of
human LDH-A in the presence of inhibitors have been
described, but currently no structures of the apo or binary
NADH-bound forms are available for any mammalian LDH-
A. Here, the apo structure of human LDH-A was solved at a
resolution of 2.1 A˚ in space group P4122. The active-site loop
adopts an open conformation and the packing and crystal-
lization conditions suggest that the crystal form is suitable for
soaking experiments. The soaking potential was assessed with
the cofactor NADH, which yielded a ligand-bound crystal
structure in the absence of any inhibitors. The structures show
that NADH binding induces small conformational changes in
the active-site loop and an adjacent helix. A comparison with
other eukaryotic apo LDH structures reveals the conservation
of intra-loop interactions. The structures provide novel insight
into cofactor binding and provide the foundation for soaking
experiments with fragments and inhibitors.
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1. Introduction
Lactate dehydrogenase (LDH) is a cytoplasmic enzyme that is
present in essentially all major phyla. It serves as a catalyst for
the NADH/NAD+-driven interconversion of pyruvate and
lactate (Everse & Kaplan, 1973). In humans, lactate dehy-
drogenase (hLDH) occurs as homotetramers or hetero-
tetramers predominantly comprising subunits encoded by the
LDH-A (or LDH-M, muscle) and LDH-B (or LDH-H, heart)
genes that assemble to form hLDH-1 (B4), hLDH-2 (AB3),
hLDH-3 (A2B2), hLDH-4 (A3B) and hLDH-5 (A4). In addi-
tion, hLDHC4 is found in spermatozoa (Goldberg & Hawtrey,
1967). The different LDH forms are summarized in Fig. 1. The
LDH-A and LDH-B subunits are similar in size and share
75% sequence identity, but have different catalytic properties;
the A (or M) subunit preferentially converts pyruvate to
lactate, while for the B (or H) form the converse is true
(Koukourakis et al., 2006). Mechanistically, LDH follows an
ordered sequential mechanism whereby NADH binding to
the cofactor-binding site precedes binding of pyruvate to the
substrate-binding site; this is followed by a conformational
change in which the active-site loop (residues 96–111 in
hLDH) closes over the active site to provide a largely desol-
vated ternary complex. Molecular-dynamics calculations and
temperature-jump relaxation spectroscopy have shown that in
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the open conformation, with no substrate or cofactor bound,
the pocket is quite solvent-exposed; however, in the closed
bound conformation the pocket is mostly buried (Pineda et al.,
2007; Qiu et al., 2007). LDH-A (LDH-5) is well conserved
across species for which amino-acid sequences are available,
with typically more than 86% sequence identity observed in
mammals. A number of mammalian LDH structures have
been solved to date, including the enzymes from human, rat
and rabbit (Read et al., 2001; Ward et al., 2012; Swiderek et al.,
2009; Dragovich et al., 2013; Fauber et al., 2013). However, all
of these structures harbour the cofactor together with an
inhibitor or alternatively are binary complexes with inhibitors,
most of which span the cofactor-binding and substrate-binding
pockets, and no apo structure of a mammalian LDH-A is
available at present. The few eukaryotic LDH-A apo struc-
tures that have been solved so far are those from ice mackerel
(71% sequence identity; PDB entry 2v65; Coquelle et al., 2007)
and spiny dogﬁsh (79% sequence identity; PDB entry 6ldh;
Abad-Zapatero et al., 1987). An apo structure of human
LDH-A is highly desirable as it could be used for soaking
experiments with fragments and inhibitors for drug-discovery
projects and may in addition reveal novel structural insights
into human LDH-A.
Recently, LDH has attracted renewed interest owing to its
prevalence in clinical tumours, where high expression often
correlates with poor prognosis (Zhou et al., 2010; Granchi et
al., 2011; Koukourakis et al., 2003; Granchi & Minutolo, 2012).
Serum and plasma hLDH-5 levels are used as tumour
biomarkers (Koukourakis et al., 2009). LDH levels are not
necessarily correlated with nonspeciﬁc cellular damage, but
rather overexpression is induced in malignant tumour
phenotypes. Similarly, ampliﬁed expression of this gene is also
found in several tumour cell lines, reﬂecting increased glyco-
lysis arising from oxygen deprivation (Sheng et al., 2009).
The provenance of hLDH-A in cancer metabolism and any
potential structural changes observed in the human apo LDH
structure, coupled with our interest in target-focused drug
discovery (Moorhouse et al., 2011), stimulated our search for
a structure of the apo form of hLDH-A to assist in future
fragment-based soaking experiments (Ward et al., 2012;
Kohlmann et al., 2013). Here, we report the 2.1 A˚ resolution
crystal structure of human LDH-A in the absence of any
cofactor or inhibitor as well as the binary-complex structure
with NADH.
2. Materials and methods
2.1. Cloning and protein expression
IMAGE clone 4096518 encoding hLDH-A was obtained
from Source Bioscience, Cambridge, England. The gene was
ampliﬁed by PCR using the forward primer 50-GGAATTC-
CATATGGCAACTCTAAAGGATCAG-30 and the reverse
primer 50-CCGCTCGAGAAATTGCAGCTCCTTTTGCATC-
30 and cloned into pET-26b using NdeI and XhoI restriction
sites. The construct was veriﬁed by sequencing. For expression,
the resulting plasmid was transformed into chemically
competent Escherichia coli BL21 CP cells. Typically, six ﬂasks
containing 800 ml 2YT medium supplemented with chlor-
amphenicol and kanamycin were inoculated with 35 ml of
overnight culture and incubated at 37C with agitation
(180 rev min1). Cell growth was monitored by measuring the
optical density at 600 nm until a value between 0.5 and 0.8 was
reached, at which point isopropyl -d-1-thiogalactopyranoside
(IPTG) was added to a ﬁnal concentration of 0.2 mM to
induce the expression of recombinant hLDH-5 enzyme. 4 h
after induction, cells were harvested by centrifugation at 4600g
for 30 min. The ﬁnal cell pellet was stored at 80C.
2.2. Protein purification and activity assay
Cell pellets were resuspended in 15–50 ml 200 mM KCl,
50 mM Tris–HCl, 20 mM imidazole at pH 8.0 and disrupted by
sonication. Clariﬁed lysate was loaded onto a nickel-immobi-
lized afﬁnity chromatography column and bound proteins
were eluted with an imidazole gradient. Peak fractions
containing hLDH-A protein were concentrated and further
puriﬁed by gel ﬁltration using a buffer consisting of 50 mM
Tris–HCl, 150 mM NaCl at pH 7.5. Pure protein at a concen-
tration of 20 mg ml1 was aliquoted and stored at 80C until
further use. The speciﬁc activity for the recombinant enzyme
was measured via UV spectrophotometry by monitoring the
depletion of NADH at 340 nm in the presence of pyruvate.
2.3. Crystallization
Crystals of full-length apo hLDH-A were grown using
sitting-drop vapour diffusion at 19C. Crystals were obtained
by mixing equal volumes of a well solution consisting of 10%
PEG 8000, 100 mM Na HEPES pH 7.5, 20% ethylene glycol,
10% acetonitrile with a protein solution comprising 8 mg ml1
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Figure 1
Schematic representation of the different forms of human LDH. The
tetrameric LDH forms are shown using four squares, each representing a
subunit of either LDH-A (dark grey), LDH-B (medium grey) or LDH-C
(light grey). Alternative names and subunit compositions are shown at
the top, and main tissue localizations are indicated at the bottom.
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hLDH-5 in the gel-ﬁltration buffer. Crystals were cryopro-
tected in a solution containing 90% well solution and 10%
PEG 550 MME and cooled to 100 K in liquid nitrogen. For
ligand soaking, compounds were dissolved in the cryoprotec-
tant solution to a concentration of 1 mM and crystals were
transferred into this solution, incubating for about 1 min prior
to cryocooling.
2.4. Data collection, structure determination and refinement
Diffraction data were collected from tetragonal crystals
either solely cryoprotected or additionally previously soaked
with NADH on beamline I04-1 at the Diamond Light Source
(DLS) at 100 K and a wavelength of 0.9173 A˚. Data were
processed using XDS (Kabsch, 2010) and scaling was
performed with SCALA from the CCP4 suite (Winn et al.,
2011). Data-collection and reduction statistics are summarized
in Table 1. The crystals belonged to space group P4122, with
unit-cell parameters a = b = 84.7, c = 276.0 A˚. The structure
was solved by molecular replacement using Phaser (McCoy
et al., 2007) from the CCP4 suite (Winn et al., 2011) with a
monomer of hLDH with ligands removed as a search model
(Read et al., 2001). The structure contained two molecules in
the asymmetric unit. After one round of rigid-body reﬁnement
with PHENIX (Adams et al., 2010), manual rebuilding was
performed in Coot, predominantly adjusting residues in the
ﬂexible-loop region (residues 99–110) and at the N-terminus.
Subsequently, further rounds of restrained reﬁnement were
performed and waters were added and adjusted. The electron
density was good throughout the entire model, which
consisted of residues Ala1–Phe331. A sulfate or phosphate ion
is potentially bound between the side chains of Arg168 and
His192 with partial occupancy, but this was not modelled.
For the crystals soaked with NADH, data were collected on
beamline I04-1 at DLS at 100 K. Rigid-body and positional
reﬁnement was carried out using PHENIX (Adams et al.,
2010) alternated with manual inspection and partial rebuilding
in Coot (Emsley & Cowtan, 2004). The ﬁnal structures were
validated using MolProbity (Chen et al., 2010). Reﬁnement
and geometric analysis statistics are summarized in Table 1.
The atomic coordinates and structure factors have been
deposited in the Protein Data Bank with accession codes 4l4r
(apo structure) and 4l4s (NADH binary complex).
3. Results
3.1. Recombinant human LDH-A preparation, crystallization
and structure solution
We cloned and expressed hLDH-A with a C-terminal His
tag for easy puriﬁcation purposes. Expression and subsequent
puriﬁcation produced highly pure protein with a typical yield
of about 4 mg per litre of culture. The speciﬁc activity of the
recombinant enzyme was measured by monitoring the
depletion of NADH in the presence of pyruvate, and was
calculated to be 163  19 mmol min1 mg1 based on
measurements in triplicate. In comparison, the activity of
the commercially available enzyme (Lee Biosolutions) was
104 mmol min1 mg1.
We initially observed a crystallization hit using PEG 8000
and ethylene glycol as precipitant agents buffered with Na
HEPES pH 7.5. The best of these crystals diffracted to 2.6 A˚
resolution and belonged to space group P212121, with unit-cell
parameters a = 85.3, b = 141.2, c = 283.8 A˚, which differed
from the unit-cell parameters of the ternary NADH–oxamate
crystal structure in the same space group reported previously
(Read et al., 2001). This crystal form contained two tetramers
in the asymmetric unit, and inspection of the electron density
revealed this to be an apo form of the enzyme (data not
shown). Efforts were subsequently focused towards obtaining
a higher resolution superior apo LDH-A crystal form for
soaking experiments. Using additive screens, the addition of
acetonitrile yielded fewer and larger crystals. Variation of the
ethylene glycol concentration ﬁnally resulted in longer needle-
like crystals with approximate dimensions of 20  300 
20 mm. Several data sets from these crystals were obtained, the
best of which extended to 2.1 A˚ resolution. These crystals
belonged to a novel crystal form of hLDH-A in the tetragonal
space group P4122, with unit-cell parameters a = b = 84.7,
c = 276.0 A˚. Data-collection statistics are summarized in
Table 1. The structure was solved by molecular replacement
and two copies of LDH-Awere found in the asymmetric unit,
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Table 1
Data-collection and reﬁnement statistics.
Values in parentheses are for the last shell.
Apo NADH-bound
Data collection
Wavelength (A˚) 0.9173 0.9173
Space group P4122 P4122
Unit-cell parameters (A˚) a = b = 84.7, c = 276.0 a = b = 84.3, c = 276.7
dmin (A˚) 2.1 2.9
Completeness (%) 94.3 (75.0) 99.8 (99.9)
Total reﬂections 368718 131336
Unique reﬂections 56269 23011
Multiplicity 6.6 (5.7) 5.7 (5.6)
hI/(I)i 14.9 (3.9) 7.7 (2.5)
Wilson plot B factor (A˚2) 29.0 44.0
Rmerge† 0.077 (0.480) 0.203 (0.770)
CC1/2‡ 0.998 (0.863) 0.988 (0.902)
Rp.i.m.§ 0.032 (0.217) 0.092 (0.350)
Reﬁnement
R factor} (%) 16.4 18.5
Rfree†† (%) 18.2 24.6
No. of residues (atoms) 662 (5160) 662 (5160)
No. of ligands (atoms) — 2 (86)
No. of waters 300 37
R.m.s.d., bond lengths (A˚) 0.009 0.0013
R.m.s.d., bond angles () 1.2 1.5
Average B factors (A˚2)
Protein 36.4 39.1
NADH — 37.0
Waters 43.6 23.5
Ramachandran plot
Preferred regions (%) 98.2 97.6
Allowed regions (%) 1.8 2.4
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ. ‡ CC1/2 is the Pearson
correlation coefﬁcient between random half-data sets. § Rp.i.m. =P
hklf1=½NðhklÞ  1g1=2
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where hI(hkl)i is the
average intensity and Ii(hkl) is the ith measurement of reﬂection hkl. } R factor =P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj. †† Rfree corresponds to the R factor based on 5.1%
of the data which were excluded from reﬁnement.
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accounting for half of the tetramer, with a solvent content of
about 64% (Matthews coefﬁcient of 3.43 A˚3 Da1). The ﬁnal
model consisted of the entire protein sequence of 331 amino
acids per monomer.
3.2. Characteristics of the apo LDH structure
The two LDH-A molecules in the asymmetric unit are
almost identical and can be superimposed with an r.m.s.d. of
0.18 A˚. B-factor analysis of the structure indicates a number of
regions with increased ﬂexibility, including the N-terminal tails
and the active-site loop, in agreement with previous obser-
vations (Read et al., 2001). The most striking feature of the
human apo LDH structure relates to the conformation of the
active-site loop comprising residues 99–110 (Fig. 2), which is
often referred to as the substrate-speciﬁcity loop. Loop
closure over the active site when substrate is bound is the
rate-limiting step in the reduction of pyruvate (Gerstein &
Chothia, 1991). In available binary complexes with NADH
and apo structures of LDH from different species this loop is
generally disordered. In the human apo structure reported
here, the active-site loop is well ordered in the electron density
and is observed in an ‘open’ conformation (Fig. 2b). The
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Figure 2
(a) Cartoon representation of the LDH-A apo-structure tetramer with
crystallographically independent molecules depicted in purple and
yellow, respectively. Active-site loops are circled and the location of the
NADH-binding pocket is indicated by white spheres. NBP denotes the
‘nicotinamide moiety binding pocket’ and ABP denotes the ‘adenine
moiety binding pocket’. (b) Close-up view of the A-weighted 2Fobs Fcalc
electron-density map of the active-site loop contoured at the 1.1 level
(grey) with residues labelled and side chains shown as sticks depicted in
purple.
Figure 3
(a) A-weighted Fobs  Fcalc electron-density map contoured at the 3
level (grey) observed after soaking the apo LDH-A crystal form with
NADH. The surrounding active-site region with residues lining the
pocket shown as sticks is depicted in purple, with the modelled NADH
depicted as yellow sticks. (b) Superposition of the crystal structures of
the apo form (grey) and the NADH-bound binary complex (purple) of
human LDH-A. The small-scale structural changes of the active-site loop
and adjacent helix are indicated by an arrow.
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active-site loops in the two molecules in the asymmetric unit
are engaged in different packing interactions and accordingly
show slightly different conformations. Nevertheless, equiva-
lent intra-loop interactions are observed. Glu103 forms a salt-
bridge interaction with Arg111 and this may contribute to
the stabilization of this conformation of the type II -turn.
Furthermore, Glu103 also engages in a hydrogen-bonding
interaction with the side chain of Asn107 and the main-chain
amine of Gln100. Leu108 packs against the side chains of
Gln99 and Ala97. In addition, this ordered conformation may
be stabilized by crystal contacts with neighbouring monomers
in the lattice, whereby two of these loop regions partly pack
against each other. In the closed conformation of the ternary
complex Gly96, Ala97, Arg98, Gln99 and Arg105 interact with
both the pyruvate mimic oxamate and NADH. The density
for the side chain of Arg105 is not well deﬁned and indicates
ﬂexibility in the apo structure. In the main conformation
observed, Arg105 forms a salt bridge with Glu191. Gln99 is
well ordered and interacts with the main-chain carbonyl of
Glu103, stabilizing the conformation of the active-site loop. In
the NADH-binding pocket, density for the side chain of Arg98
is poorly deﬁned in the structure, indicating ﬂexibility in the
apo form of the enzyme. Other active-site residues, including
Arg168 and the catalytic His192 and Thr247, are well deﬁned
in the electron density.
3.3. The apo structure is amenable to ligand soaking
In the crystal packing, large solvent channels are available
to allow access to the active site. The high solvent content
together with the neutral pH, low salt concentration and
presence of relatively hydrophobic agents in the crystallization
condition renders this crystal form highly suitable for soaking
with small-molecule ligands. We investigated this possibility
using the cofactor NADH as a proof-of-principle ligand and
measured a data set from a crystal that had been soaked with
NADH to 2.9 A˚ resolution. This experiment resulted in clearly
identiﬁable additional electron density in the active site of
hLDH-A, as shown in Fig. 3(a). The average B factors for
NADH are similar to the B factors of surrounding residues,
indicating full occupancy of the ligand. A superposition of the
apo and NADH binary-complex structures focusing on the
active-site region is shown in Fig. 3(b). The active-site loop
remains in the open conformation after soaking, probably
owing to its involvement in crystal contacts. In helix D (the
historical nomenclature is employed throughout the manu-
script; Supplementary Fig. S11) small-scale but signiﬁcant
movements of about 1.8 A˚ between residues Ile119 and
Arg105 were observed after soaking with NADH, propagating
a slight bending motion of the entire loop region until residue
Ala105 (indicated by an arrow in Fig. 3b). The intra-loop
interactions such as the salt bridge between Arg111 and
Glu103 are thereby maintained. The presence of NADH
displaces at least seven water molecules, although a full
analysis of the water-interaction network is hampered by the
moderate resolution of the NADH binary-complex structure.
In contrast to the apo structure, the side chain of Arg98
engages in contacts with the NADH phosphates and appears
to be more ordered, with the density being better resolved.
In addition to the active-site loop and helix D movements, a
number of residues display rotamer changes upon binding of
NADH, including residues Val25, Ile53, Glu54, Lys56, Ile115,
Asn137, Ser160, Leu164, Thr247, Ile251, Ile325, Glu328 and
Gln330.
3.4. Comparison between the apo and binary and ternary
complex structures
The apo and binary NADH-bound structures presented
here in combination with the previously determined ternary
complex (PDB entry 1i10; Read et al., 2001) allow a direct
comparison between the apo and NADH-bound binary and
ternary complex structures of human lactate dehydrogenase
A. A monomer from the apo structure can be superimposed
with monomers from the oxamate and NADH-bound struc-
ture in a different space group with an r.m.s.d. of 0.5 A˚ over
300 residues (excluding residues from the active-site loop and
N-terminus). This superposition highlights the large-scale
conformational changes observed in the loop region (Fig. 4).
In the closed conformation of the ternary complex, residues
Gln99, Arg105, Asn137, Arg168, His192 and Thr247 are
engaged in hydrogen-bonding interactions with oxamate,
while Leu164 and Ala237 are engaged in hydrophobic
contacts. The side chain of Arg168 interacts with the carbox-
ylate group of the ligand. A protonated His192 is the cataly-
tically important proton donor in the pyruvate-to-lactate
conversion and together with Arg105 is crucial for pyruvate
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Figure 4
Superposition of the human LDH-A apo form (grey) and NADH binary
complex (purple) reported here with the ternary complex bound to
NADH and the competitive inhibitor oxamate (two different monomers
shown in blue and light blue, respectively; PDB entry 1i10; Read et al.,
2001), highlighting the conformational changes upon cofactor and
substrate binding, with key residues shown in stick representation.
1 Supporting information has been deposited in the IUCr electronic archive
(Reference: MN5051).
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binding. In the binary-complex and apo structures, Arg105
is exposed to bulk solvent and interacts with Glu191. The
guanidinium moiety undergoes movements of over 10 A˚ from
the surface to a buried position upon substrate binding.
Glu101 at the tip of the loop moves over 8–11 A˚ between the
open and closed forms in both independent molecules of the
asymmetric unit. In one monomer of the ternary NADH/
oxamate structure the active site is substantially more open
(PDB entry 1i10 chainD; Read et al., 2001), possibly capturing
an intermediate conformational state before loop closure.
Hence, together with the structures presented here, four forms
of human LDH-A can be compared with the caveat that the
mobile loop is involved in crystal contacts. The two NADH
molecules in our binary complex and in the half-open
monomer of the ternary complex superimpose well, whereas
in the closed form of the ternary complex NADH appears to
be shifted deeper into the binding pocket. Loop closure is
associated with additional small movements in the D helix
(Ala95–Ile119) and the C-terminal H helix (Fig. 4). In
addition, local differences are observed in a number of side-
chain conformations, including Ile53, Lys56, Asn137, Arg168,
Ser236, Ala237, Tyr238 and Ile241. The catalytic residue
His192 slightly shifts towards the substrate mimic by about
1.1 A˚ only in the closed conformation of the active-site loop.
This coincides with a shift of Asn137, while the conformation
of Asp165 remains virtually unchanged.
3.5. Comparison with other eukaryotic LDH-A structures
Whereas structures of ternary complexes and binary
complexes with inhibitors of mammalian LDH-A orthologues
have been determined, no other apo structure is available for
comparison. There are some residues that are affected by
small structural changes upon NADH and substrate binding
and are not absolutely conserved among mammals, including
residues Ile53 and Ser248 (Fig. 5a, Supplementary Fig. S1).
Residues in the active-site loop and -helix D are absolutely
conserved among mammals, with the exception of Val123.
Additionally, Ile149, which backs onto this -helix, is not
absolutely conserved. Residues 12–19 display high B factors,
but the positions of the active-site residues are almost iden-
tical in these ternary inhibitor structures. The closest LDH-A
apo structures available at present are from Squalus acanthias
(spiny dogﬁsh; PDB entry 6ldh; 79.9% sequence identity;
Abad-Zapatero et al., 1987) and from Champsocephalus
gunnari (ice mackerel; PDB entry 2v65; 71.5% sequence
identity; Coquelle et al., 2007). The sequence in the active-site
loop is absolutely conserved, but a much higher degree of
sequence variation occurs in other parts of the enzyme
compared with mammalian LDH-As. Despite different
crystal-packing arrangements in the human and dogﬁsh apo
structures, the active-site loop regions nevertheless adopt
similar conformations, with a local r.m.s.d. of 0.4 A˚ over the C
atoms of 20 residues. Interestingly, the salt bridge between
Glu103 and Arg115 (Fig. 5b) is also conserved among these
three apo crystal structures, even though residues 101–105 are
disordered in the structure from ice mackerel. This suggests
that despite its ﬂexible nature, the crystal structures may
capture a preferred conformation of the active-site loop in apo
forms of this enzyme.
4. Discussion
Lactate dehydrogenase has been studied for many decades
(Markert &Møller, 1959) as it is abundant in tissue cells and is
a marker for cell damage. Its position in the glycolytic cascade
renders it a viable anticancer target, which has initiated a
renaissance of research into this important enzyme. In this
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Figure 5
(a) Cartoon representation of a monomer of the human LDH-A binary
complex (purple) with NADH (grey) with positions of sequence variation
among mammalian LDH-A enzymes shown as sticks and coloured in
orange. Selected residues in close proximity to the active site are labelled.
(b) Superposition of the human LDH-A apo form (purple) with LDH-A
apo structures from spiny dogﬁsh (cyan; PDB entry 6ldh; 0.45 A˚ r.m.s.d.,
79% sequence identity; Abad-Zapatero et al., 1987) and ice mackerel
(light blue; PDB entry 2v65; 0.6 A˚ r.m.s.d., 71% sequence identity;
Coquelle et al., 2007).
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study, we close an important gap by presenting the apo and
binary NADH-bound structures of human LDH-A. Moreover,
the structure of the apo form together with our soaking
experiment with NADH demonstrates that the active site is
accessible to small-molecule ligands in this crystal form.
Recently, ligand-bound crystal structures of rat LDH have
been reported (Ward et al., 2012), and rabbit LDH-A has also
been used as model system for inhibitor design (Kohlmann et
al., 2013). The rat LDH-A crystals belonged to space group
P21; they were grown in high-salt conditions with four mole-
cules in the asymmetric unit and showed a closed conforma-
tion of the active site. LDH-A crystals grown in the presence
of AMP from rabbit that belonged to space group P21 with
two tetramers in the asymmetric unit and a disordered active-
site loop have also been used for soaking experiments.
Although both rat and rabbit LDH-A are highly homo-
logous and the active-site residues are largely conserved
compared with human LDH-A, there are nevertheless small
differences in the active-site region (Fig. 5a, Supplementary
Fig. S1). Single amino-acid substitutions can have long-range
effects on protein structure, dynamics and ligand interactions
that can potentially have consequences for using these systems
as surrogates for drug design. In our crystal form the loop is
observed in an open conformation, readily allowing access to
the binding pocket, and is stabilized through crystal contacts.
Our results show that LDH-A is able to bind NADH in this
open conformation. As loop closure is restricted, ligands
interacting with the pyruvate and/or nicotinamide binding
pocket may display a decreased afﬁnity. However, substrate
mimics can bind in this conformation, as observed in mono-
mers with an open active-site loop in human and rabbit
ternary-complex structures (Swiderek et al., 2009; Read et al.,
2001). This demonstrates that loop closure is not a prerequi-
site for substrate-mimic binding. It has been suggested that
multiple binding pathways for the substrate are likely (Qiu et
al., 2007). The apo structure described here will provide an
important platform for drug design and the understanding of
this key enzyme in glycolysis.
Our ligand-bound structure reveals NADH bound in an
almost identical fashion to that seen previously in the ternary
complex in the open conformation, implying that the presence
or absence of oxamate does not have a signiﬁcant impact on
the NADH conformation. The binding of NADH only triggers
small-scale local changes, indicating that the mobility of the
active-site loop is hardly restricted by the presence of bound
NADH. This is also supported by B-factor analysis, which
shows that the average B factors of the loop residues are
comparable between the NADH-bound and apo structures.
Rather, the NADH position is slightly affected by loop
closure, which coincides with a slight repositioning of the
catalytic residues, including His192. This is in line with this
being the rate-limiting step in the catalytic cycle. Although the
loop has often been observed to be disordered in the open
conformation, our data suggest that some intra-loop inter-
actions are conserved, indicating that preferred conformations
of the apo and NADH-bound active-site loop exist. Some of
these interactions are maintained after loop closure, such as
the salt bridge between Glu103 and Arg111.
Taken together, our structural study of human LDH-A
in the apo form and in complex with NADH adds to our
understanding of the conformational changes during catalysis
and the conservation of intra-loop interactions across higher
eukaryotes and will provide a valuable tool for inhibitor
design.
This work was carried out with the support of the Diamond
Light Source and was supported in part by BBSRC grant
BB/H012656/1 to ID. We thank the University of Nottingham
for funding SD.
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